CHI3L1 and breast cancer: Previous studies investigating the influence of YKL-40 expression on clinical outcome of patients with breast cancer have reported varying even conflict results, and there is still lack of high-quality evidence for YKL- 40 as a molecular biomarker in breast cancer patients.